Heartport cost reductions please Wall Street
This article was originally published in Clinica
Executive Summary
Heartport, a minimally-invasive cardiac surgery company called 1998 a "pivotal year", as it published its year-end figures, showing that sales had dropped to $19 million from $23 million. During 1998 the company was forced to restructure and cut staff by a third, as surgeon acceptance of the company's Port-Access procedure was questioned (see Clinica No 807, p 13). Nonetheless, one prominent New York analyst is pleased with how the Redwood City, California-based company has "reined in costs" and with the launch of its new product, the EndoDirect system. While the last quarter's figures showed sales of just under $5 million, compared with the $8 million of the previous year, Glenn Reicin of Morgan Stanley Dean Witter said that the figure was some $500,000 better than the analysts' estimate. Losses from operations for the quarter were $4 million and $12 million for the year.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.